CellCarta

Mass spectrometry platform supporting large-scale proteomic analysis and biomarker quantification projects.

Comprehensive genomic and transcriptomic profiling including whole genome and exome sequencing, ctDNA/MRD tracking, RNA sequencing, and single-cell sequencing.

Deep transcriptomic analysis including bulk RNA sequencing and single-cell RNA sequencing to understand pathways triggered by ADCs.

Next-generation sequencing tool for rapid and high-throughput sample processing from a small starting volume for tissue and liquid biopsies.

Customizable immunohistochemistry (IHC) and immunofluorescence (IF) assay development and testing services for clinical trials with over 200 validated assays.

Insights into the abundance, distribution, and localization of your antigen of interest.

Multiplexed, high-sensitivity, quantitative immune analysis service utilizing electrochemiluminescent (ECL) detection for cytokine and chemokine measurements from limited sample input.

Measure up to ten analytes per well using sample volumes as small as 25 μL.

Panels that quantify up to 92 carefully selected proteins across up to 88 samples simultaneously, using only 1µL of sample.

Olink Target 96 panel designed for immuno-oncology research and biomarker discovery.

Olink Target 96 panel tailored for exploratory mouse biomarker research.

Olink Target 96 panel for cardiovascular disease research.

Olink Target 96 panel focused on cardiometabolic disease biomarkers.

Spectral and conventional platforms with up to 40 parameters per cell, supporting validated checkpoint, TIL, CAR-T, and receptor occupancy panels.

Target expression assessment in the periphery or biopsy samples, including receptor occupancy assays.

Pan-cancer solid tumor IVD/FDA assay from Pillar Biosciences used for clinical validation and patient selection.

Assay for the detection of deletions and mutations for patient management in NSCLC and CRC.

High-quality unbiased liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) services to help discover new biomarkers.

Qualitative in vitro diagnostic test for the detection of mutations in exons 7, 9, 15 and 20 using DNA extracted from FFPE samples and ctDNA from plasma.

PCR kit for FGFR assessment using RNA from FFPE samples, targeting point mutations in exon 7, 10, and FGFR-TACC fusions.

PCR kit for assessing KRAS gene mutations using DNA from FFPE samples, targeting mutations in codons 12 and 13.

PCR kit designed for the assessment of EGFR gene mutations using DNA from FFPE samples, targeting indels in exon 19 and 20 and point mutations.

PCR kit for BRAF assessment using DNA from FFPE CRC tumor tissues, targeting V600E mutations.

Test for assessing EGFR gene mutations utilizing DNA from FFPE and plasma samples, supporting indels in exon 19 and 20, point mutations, and semi-quantitative analysis for ctDNA samples.

PCR-based test for the detection of mutations in codons 12, 13, and 61 using DNA extracted from FFPE samples.

Qualitative test for the detection of BRAF V600E using DNA extracted from FFPE samples such as CRC and melanoma.

Comprehensive single or dual ISH services to visualize and quantify nucleic acids with precision, offering fluorescence, chromogenic, and silver ISH assays.

Biomarker and MRD analysis from ctDNA and CTCs using RareCyte and TSO500 NGS panels.

Comprehensive RNA sequencing (RNAseq) services for gene expression profiling, transcriptomic analysis, biomarker discovery, and precision medicine research.

Clinical RNA sequencing services delivering low duplication rates and unique read coverage.

Large-scale transcriptomic analysis of individual cells to unveil in-depth information from complex biological samples.

Advanced spatial biology technologies including Visium, GeoMx, and COMET for high-resolution mapping and transcriptomic/proteomic profiling.

Reliable, high-throughput measurement of critical biomarkers using ELISA (enzyme-linked immunosorbent assays) optimized for preclinical and clinical applications.

Single-cell sequencing services for high-resolution genomic and transcriptomic profiling.

Reveal how cells interact in their native tissue environment with spatial biology tools built for clinical research.

A hybrid, centralized/decentralized companion diagnostic (CDx) development service spanning the full lifecycle from biomarker strategy and assay development to regulatory submission and commercial launch.

Resolve cellular heterogeneity and immune repertoire dynamics using the 10x Genomics Chromium platform and Cell Ranger software.

Map gene expression in tissue context using genomic data analysis software across spatial platforms, including GeoMx and Visium HD.

Next-generation sequencing services for translational and clinical studies.

A precise, high-throughput solution to analyze samples at scale and speed to support biomarker discovery, patient stratification, and therapeutic development.

Targeted, high-plex RNA and protein expression analysis platform in hypothesis-driven regions of interest.

Spatial gene expression platform that maps the whole transcriptome for your entire sample at single-cell resolution.

Assay validated as a clinical trial assay for patients with non-small cell lung cancer (NSCLC) for accurate, rapid, and sensitive detection of NSCLC variants.

Proven and emerging molecular platforms for clinical sample analysis and reporting.

A validated 45-cytokine multiplex PEA panel in NSCLC plasma delivering high sensitivity, precision, and differential immune profiling.

CellCarta leverages high-speed cell sorters and in-depth flow expertise to deliver high-purity cell populations with the throughput and reliability needed for industrial applications.

Quantitative proteomics services that support multiplex biomarker testing across diverse clinical sample types using advanced immunoassays and LC-MS platforms.

Automated multiplex immunofluorescence platform with high reproducibility at single-cell resolution supporting protein and RNA targets.

Qualitative and quantitative analyses of samples at the single-cell level using multiparametric flow cytometry and spectral flow platforms.

A longitudinal analysis service of liquid biopsy samples providing circulating tumor cell enumeration, phenotypic characterization, and optional cell-free DNA analysis using the RareCyte platform.

Detect variants across the full genome or coding regions with pipelines built for clinical-grade reporting.

Complete cell therapy services across all clinical stages, offering custom development, product characterization, patient selection, safety assessment, efficacy and response monitoring, and drug product monitoring.

End-to-end histopathology services from a team with deep clinical trial expertise across multiple indications.

Generate validated, auditable outputs for CAR-T development, viral vector quantification, and genome editing programs.

Explores over 1,000 proteins from as little as 4 µL of sample with deep coverage across inflammation, immune responses, and oncology.

Isolate and purify targeted cell populations with high-speed, high-purity cell sorting.

Precise localization and quantification of nucleic acids including DNA, mRNA, and microRNA.

Platform combining cellular indexing of transcriptomes and epitopes by sequencing to assess immune cell populations and guide patient selection.

Flow cytometry-based assay services for in-depth understanding of cytokine expression at the single-cell level, quantifying cytokine-producing cells and functional profiling of immune cell subsets.

Profile transcriptomes using gene expression analysis software for RNAseq and NanoString nCounter.

Ultrasensitive and absolute nucleic acid quantification service using off-the-shelf or custom panels for mutation detection, low abundance gene quantification, and copy number variation determination.

Multiparametric flow cytometry services providing phenotypic and functional insights into immune cell subsets and markers.

Characterize innate and adaptive immune populations with cutting-edge flow cytometry platforms for enriched understanding of immune cell identity and behavior at single-cell resolution.

Platform utilized for single-cell sequencing applications.

Customizable options allowing selection of up to 21 proteins from a library of validated biomarkers or deployment of custom panels developed by Olink.

Single-cell sequencing implemented to identify key immune reset metrics and characterize B-cell populations.

Combined metal-isotope-tagged antibodies and time-of-flight detection to characterize up to 50 markers simultaneously for high-content cytometric analysis.

Sensitive and robust assessments of the frequency of cytokine-secreting cells at the single-cell level provided as a service by CellCarta.

Pre-developed and validated flow cytometry panels available at all global sites to support the monitoring of immune cell populations in whole blood and cryopreserved PBMC samples.

Spatial Phenotyping and Analysis in Regions of Tissue with AI, CellCarta's framework for mIF analysis.

Tissue biomarker data from 200+ validated IHC and IF assays scored by board-certified pathologists.

Validated immunoassay platforms for precise biomarker quantification and clinical testing.

A next-generation, automated, benchtop multiplexing ELISA system that delivers high-speed precision with minimal user input using Simple Plex cartridges.

Off-the-shelf NGS assays from Pillar Biosciences for solid tumor and liquid biopsy applications.

Large-scale multiplex discovery proteomics platform with the capacity to investigate over 5,400 analytes simultaneously.

Target expression assessment in solid tumors using immunohistochemistry and immunofluorescence for ADC development.

An RNA library preparation kit featuring Polaris depletion for whole transcriptome sequencing, providing reduced turnaround times, efficient rRNA and globin depletion, and high reproducibility for challenging clinical samples such as FFPE and whole blood.

Discover new biomarkers with multi-omic assays.

Sourced biospecimens for assay development, from PBMCs to fresh tumors, with full consent review.

Multiplexed immunohistochemistry and immunofluorescence biomarker assays designed to interrogate multiple targets on a single slide for comprehensive tumor microenvironment and cellular infiltration analysis.

Quantify protein biomarkers using just 1µL of blood with high sensitivity and specificity.

Comprehensive genomic profiling assay designed to assess multiple mutations for large-scale analysis.

Maximize genomic data output through customized PCR assays and comprehensive NGS testing.

Cutting-edge digital pathology solutions and image analysis services for clinical studies, featuring whole slide high-resolution image capture and pathologist-directed image analysis.

End-to-end PBMC processing services that protect clinical sample integrity and viability from collection to analysis, achieving over 90% PBMC viability.

Pre-developed and validated flow cytometry panels at specific sites that can be rapidly deployed upon request for clinical sample analysis.

Catalog of custom assays detecting key oncogenes including EGFR, KRAS, BRAF, FGFR, and PIK3CA.

Global team of experienced pathologists with training in CDx scoring methods.

A validated high-sensitivity TBNK assay designed for exploratory endpoints in studies investigating B-cell aplasia.

Quantification of cytokines, chemokines, and soluble immune biomarkers across validated immunoassay platforms and mass spectrometry.

Targeted NGS liquid biopsy panel covering RNA fusions.

Olink Target 48 panels for targeted protein biomarker discovery and validation.

Multiplex assay panel targeting angiogenesis markers including FGF, PlGF, Tie-2, and VEGF variants.

Cutting-edge digital and AI-powered analysis to advance your clinical trials.

A comprehensive pan-cancer NGS panel enabling simultaneous analysis of DNA and RNA variants across hundreds of genes for complex molecular signatures.

A quantitative MS workflow for the highly multiplexed measurement of immunomodulatory proteins in clinical trials.

Comprehensive analysis of all genomic data tailored to specific project needs.

An IVDR and FDA approved, next-generation sequencing-based companion diagnostic test developed to provide rapid, clinically actionable insights across a wide range of solid tumors.

Fully integrated MS platforms and immunoassays for discovery and bioanalytical testing.

Targeted and quantitative approach to measure clinically relevant biomarkers using formalin-fixed paraffin embedded (FFPE) samples.

Custom assays developed to investigate drug-target engagement and therapeutic PK/PD relationships using flow cytometry.

Standard TBNK panel with IVD status, validated for secondary endpoint use and precise enumeration of T-cells, B-cells, and NK cells.

Assay service coupling immunoaffinity enrichment of peptides to LC-MRM for unambiguous biomarker quantification and detection of PTMs.

HLA typing assays for clinical use and patient stratification.

Multiplex assay panel for the simultaneous detection of various chemokines.

Personalized, standard operating procedure (SOP)-backed training services for clinical sites to collect, process, and ship samples correctly.

Cutting-edge technology to understand the transcriptome and its biological context.

Accurately quantify specific immune cell populations across whole blood and PBMC samples.

End-to-end proteomics support, from sample processing to data analysis using mass spectrometry.

Companion diagnostic and mutation detection kits for EGFR, PIK3CA, KRAS, and FGFR.

Expand preclinical datasets with genomic analysis.

Combine immunoaffinity enrichment with LC-MS for sensitive quantification.

Multiplex assay panel for measuring phosphorylated STAT proteins.

Assess immune cell division and cycling to evaluate treatment response and immune activation.

Mutation testing assays covering PIK3CA, BRAF V600, KRAS, EGFR, and BRAF/NRAS.

RNA exome sequencing panel by Illumina.

Multiplex assay panel targeting Th17-related interleukins.

Assays for targeted genomic analysis and mutation detection.

Multiplex biomarker panel for evaluating kidney injury and nephrotoxicity.

Support for qPCR applications using off-the-shelf assays or custom, validated primers.

TBNK + CD20 panel for improved B-cell identification, validated for secondary endpoint use.

Analyze expression and morphology via IHC.

CellCarta validated the TBNK + CD20 enumeration assay as a highly sensitive method for peripheral B-cell monitoring in B-cell-depleting therapy (BCDT) clinical trials.

Monitor the expression of soluble B-cell maturation antigen (BCMA) in clinical plasma samples using the MRM platform.

Diverse suite of fit-for-purpose precision assays to characterize and optimize your ADC platform.

Comprehensive panel for lung cancer biomarker assessment using qPCR.

Multiplex assay panel designed for measuring multiple cytokines simultaneously.

Panel for comprehensive exome capture and sequencing.

CellCarta's Virtual Central Sample Management platform provides start-to-finish oversight, sample reconciliation, and electronic inventory records for clinical samples.

Multiplex assay for the detection of various interferon types.

A qualified carboxyfluorescein succinimidyl ester (CFSE) assay that quantifies cell proliferation by tracking dye dilution across successive cell divisions.

An analysis using Ki-67 as an early activation marker to identify cells that enter a new cell cycle across active phases.

RNA library preparation kit for high-performance sequencing workflows.

Human T-Plex kit for the measurement of sAPP-α and sAPP-β.

Bromodeoxyuridine (BrdU)-based DNA synthesis measurement capturing newly proliferating cells through incorporation into freshly synthesized DNA.

Multiplex assay designed to measure key proinflammatory biomarkers and interleukins.

Evaluate compound activity in blood.

Multiplex assay panel targeting vascular and endothelial injury markers including CRP, ICAM-1, SAA, and VCAM-1.

Characterize MHC-bound peptides with a high-throughput workflow using automated immunoaffinity enrichment via a KingFisher magnetic particle processor.

Digital pathology scoring and annotation platform developed by CellCarta for internal and client training programs.

TBNK + monocyte panel enabling monocyte and NK cell enumeration.

Assess stability of therapeutics via MS.

Measure basophil degranulation to assess allergic and hypersensitivity immune responses.

Measure basophil degranulation to assess allergic and hypersensitivity immune responses.